Immutep (ASX:IMM) has announced the initiation of its TACTI-004 Phase III clinical trial, which aims to evaluate the efficacy ...
Visioneering Technologies (ASX:VTI) has announced plans to delist from the ASX, with a vote scheduled for 10 January 2025.